| Literature DB >> 34253859 |
Liyuan Wang1,2, Yang Sun1,2, Xiaojia Song1,2, Zehua Wang1,2, Yankun Zhang1,2, Ying Zhao1,2, Xueqi Peng1,2, Xiaodong Zhang1,2, Chunyang Li1,2,3, Chengjiang Gao1,2,3,4, Nailin Li5, Lifen Gao1,2,3, Xiaohong Liang1,2,3, Zhuanchang Wu6,7, Chunhong Ma8,9,10,11.
Abstract
HBV is considered as a "stealth" virus that does not invoke interferon (IFN) responses; however, the mechanisms by which HBV bypasses innate immune recognition are poorly understood. In this study, we identified adenosine deaminases acting on RNA 1 (ADAR1), which is a key factor in HBV evasion from IFN responses in hepatocytes. Mechanically, ADAR1 interacted with HBV RNAs and deaminated adenosine (A) to generate inosine (I), which disrupted host immune recognition and thus promoted HBV replication. Loss of ADAR1 or its deficient deaminase activity promoted IFN responses and inhibited HBV replication in hepatocytes, and blocking the IFN signaling pathways released the inhibition of HBV replication caused by ADAR1 deficiency. Notably, the HBV X protein (HBx) transcriptionally promoted ADAR1 expression to increase the threshold required to trigger intrinsic immune activation, which in turn enhanced HBV escape from immune recognition, leading to persistent infection. Supplementation with 8-azaadenosine, an ADAR1 inhibitor, efficiently enhanced liver immune activation to promote HBV clearance in vivo and in vitro. Taken together, our results delineate a molecular mechanism by which HBx promotes ADAR1-derived HBV immune escape and suggest a targeted therapeutic intervention for HBV infection.Entities:
Keywords: ADAR1; HBV replication; HBx; IFN response; RNA editing
Mesh:
Substances:
Year: 2021 PMID: 34253859 PMCID: PMC8322072 DOI: 10.1038/s41423-021-00729-1
Source DB: PubMed Journal: Cell Mol Immunol ISSN: 1672-7681 Impact factor: 22.096